Study population and transplant characteristics
| Characteristic . | Value . |
|---|---|
| Sample size, n | 24 |
| Patient age, y, median (range) | 47 (23-63) |
| Patient sex (male), n (%) | 17 (71) |
| Donor sex (male), n (%) | 14 (58) |
| Female donor → male patient | 7 (29) |
| CMV seronegative donor-recipient pair | 8 (33) |
| Diagnosis | |
| Myeloid malignancies | 6 (25) |
| AML | 4 (17) |
| MPN | 1 (4) |
| CML | 1 (4) |
| Lymphoid malignancies | 18 (75) |
| ALL | 5 (21) |
| Hodgkin disease | 2 (8) |
| Follicular lymphoma | 2 (8) |
| CLL | 2 (8) |
| Multiple myeloma | 7 (29) |
| Disease status at transplant | |
| CR | 12 (50) |
| PR | 8 (33) |
| Progressive | 3 (13) |
| Never treated | 1 (4) |
| Stem cell source | |
| PBSC | 18 (75)* |
| BM | 5 (21) |
| Double UCB | 1 (4) |
| Donor type | |
| HLA-matched relative | 10 (42) |
| HLA-matched unrelated donor | 9 (37) |
| HLA-mismatched unrelated donor | 5 (21)† |
| Cell dose, median (range)‡ | |
| TNC, ×108/kg | 7.3 (0.8-14.0) |
| CD34+ cells, ×106/kg | 4.5 (0.1-10.0) |
| Conditioning regimen | |
| MAC | 11 (46) |
| RIC | 13 (54) |
| TBI-based regimen | |
| Yes | 6 (25) |
| No | 18 (75) |
| Use of ATG | |
| Yes | 8 (33) |
| No | 16 (67) |
| GVHD prophylaxis | |
| CsA + MMF | 16 (67) |
| CsA + MTX | 4 (17) |
| CsA | 4 (17) |
| Characteristic . | Value . |
|---|---|
| Sample size, n | 24 |
| Patient age, y, median (range) | 47 (23-63) |
| Patient sex (male), n (%) | 17 (71) |
| Donor sex (male), n (%) | 14 (58) |
| Female donor → male patient | 7 (29) |
| CMV seronegative donor-recipient pair | 8 (33) |
| Diagnosis | |
| Myeloid malignancies | 6 (25) |
| AML | 4 (17) |
| MPN | 1 (4) |
| CML | 1 (4) |
| Lymphoid malignancies | 18 (75) |
| ALL | 5 (21) |
| Hodgkin disease | 2 (8) |
| Follicular lymphoma | 2 (8) |
| CLL | 2 (8) |
| Multiple myeloma | 7 (29) |
| Disease status at transplant | |
| CR | 12 (50) |
| PR | 8 (33) |
| Progressive | 3 (13) |
| Never treated | 1 (4) |
| Stem cell source | |
| PBSC | 18 (75)* |
| BM | 5 (21) |
| Double UCB | 1 (4) |
| Donor type | |
| HLA-matched relative | 10 (42) |
| HLA-matched unrelated donor | 9 (37) |
| HLA-mismatched unrelated donor | 5 (21)† |
| Cell dose, median (range)‡ | |
| TNC, ×108/kg | 7.3 (0.8-14.0) |
| CD34+ cells, ×106/kg | 4.5 (0.1-10.0) |
| Conditioning regimen | |
| MAC | 11 (46) |
| RIC | 13 (54) |
| TBI-based regimen | |
| Yes | 6 (25) |
| No | 18 (75) |
| Use of ATG | |
| Yes | 8 (33) |
| No | 16 (67) |
| GVHD prophylaxis | |
| CsA + MMF | 16 (67) |
| CsA + MTX | 4 (17) |
| CsA | 4 (17) |
ALL, acute lymphoid leukemia; AML, acute myeloid leukemia; ATG, antithymoglobuline; BM, bone marrow; CLL, chronic lymphocytic leukemia; CML, chronic myeloid leukemia; MAC, myeloablative conditioning; MMF, mycophenolate mofetil; MPN, myeloproliferative neoplasm; MTX, methotrexate; RIC, reduced-intensity conditioning; TBI, total body irradiation; TNC, total nucleated cell; UCB, umbilical cord blood.
Due to low PBSC mobilization, 1 patient in this group received PBSC + BM.
Four patients received a single HLA-mismatch unrelated donor (9/10) transplant, and 1 patient received 2 UCB transplant mismatched at 2 HLA loci each (4/6).
For the patient who received 2 UCB transplants, the TNC and CD34 dose of each cord blood unit were added.